Kornimate/medical-research-clean huggingface dataset:
evaluation of fusion rate of anterior cervical discectomy and fusion (acdf) using cervios chronos™ and bonion™

Conditions: Intervertebral Disk Degeneration; Intervertebral Disk Displacement; Ossification of Posterior Longitudinal Ligament

Summary: anterior cervical discectomy and fusion (acdf) has shown good treatment results for a variety of cervical spine diseases such as herniated intervertebral disc (hivd), cervical spondylotic radiculopathy (csr) and cervical spondylotic myelopathy (csm). acdf using autogenous iliac bone graft is gold standard, however, it may lead to donor-site morbidities. preventing these complications, some authors have tried to use alterative bone graft substitutes. among these alternatives, cervios chronos™ which is the polyetheretherketone (peek) cage with b-tricalcium phosphate (tcp) has become popular and shown good clinical results. however, b-tcp has only osteoconduction ability of three osteogenic properties. recently, bonion™ which is the peek cage filled with hydroxyapatite (ha) / demineralized bone matrix (dbm) is introduced. ha/dbm mixture has abilities of osteoconduction and osteoinduction, therefore this alternative is expected to show superior bone fusion capability to peek cage with b-tcp. however, there has been no comparison study between the peek cage with b-tcp and the peek cage with ha/dbm. the purpose of this study is to evaluate bone fusion rate between these cervical spine cages using postoperative computed tomography (ct)

biologically, graft material should be endowed with several basic properties. several synthetic materials and graft substitutes have been developed to maximize fusion outcomes while avoiding complications of harvesting autograft. mixture of hydroxyapatite (ha) and β-tricalcium phosphate (β-tcp), have been widely utilized for bony regeneration. on the other hand, demineralized bone matrix (dbm) has been utilized as a graft substitute with mainly its osteoinductive ability. while ha and β-tcp have osteoinductive osteoconductive properties and dbm has osteoconductive osteoinductive properties, a graft material fully incorporating both properties has not been developed. we hypothesize that an interbody graft material equipped simultaneously with osteoinductivity and osteoconductivity would enhance fusion achievement; however, clinical trials with mixture materials within a peek cage in acdf surgery have rarely been performed.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of cervical hivd, csr, csm or opll * the patient who is expected to receive anterior cervical discectomy and fusion operation. * volunteer for this study with written consent. exclusion criteria: * patient with cervical spine fracture, infection. * below -3.5 t-score by dexa bone densitometry * patient with hemorrhagic diseases * patient with malignancy * patient who is not suitable for this study judged by principal investigator

Keywords: anterior cervical discectomy and fusion bone graft substitute peek cage hydroxyapatite demineralized bone matrix b-tricalcium phosphate bonion cervios chronos
pr in endoscopic lar for rectal cancer

Conditions: Rectal Carcinoma

Summary: the anastomotic leakage remains the major early complication after laparoscopic anterior resection(lar) for medium \& low rectal cancer. pelvic floor reconstruction (pr) is a key step in various standard resections for open radical rectal cancer surgery, which was considered to be helpful for decreasing the rate of leakage. however, pr in endoscopic lar surgery is not routine practice and remains controversial. the purpose of this study is to evaluate the efficacy of pr during lar for mid/low rectal carcinoma, especially in preventing anastomotic leakage.

eligible patients with rectal cancer will be randomly assigned to group with pelvic floor reconstruction(pr) versus group without pelvic floor reconstruction(npr). we want to investigate the rate of anastomotic leakage and re-operation between the two groups, some other relevant outcomes will be concerned all the same.

Eligibility criteria:
inclusion criteria: 1. patients with histologically proven rectal adenocarcinoma 2. tumor located in the middle and lower rectum and anastomosis under the peritoneal reflection 3. tumor assessed as a depth of invasion that was confined to pt1-pt3, bn0-1m0 by ultrasound colonoscopy and/or pelvic mri 4. negative circumferential resection margin confirmed by mri 5. performance status (ecog) 0\~1 6. written informed consent for participation in the trial exclusion criteria: 1. history of accepting lower abdominal surgery. 2. more than one colorectal tumor 3. patients with unresectable distant metastasis or multiple metastases 4. received neoadjuvant radiotherapy before surgery 5. signs of acute intestinal obstruction, bleeding or perforation needing emergency surgery 6. patients and/or family members cannot understand and accept this study 7. non-rectal adenocarcinoma was confirmed by postoperative pathological examination

Keywords: minimally invasive surgical
gut microbiota and new hypertension

Conditions: Hypertension; Gut Microbiota

Summary: this study aims to explore the gut microbiota patterns in patients newly diagnosed with hypertension, comparing them to those in non-hypertensive individuals. utilizing cross-sectional analysis, it seeks to identify specific microbial profiles associated with hypertension, which could provide insights into the disease's pathogenesis and potential new avenues for treatment. the research focuses on analyzing fecal samples collected from both groups, using advanced genomic techniques to assess the diversity and abundance of gut bacteria. this investigation could contribute significantly to our understanding of the role gut microbiota plays in cardiovascular health and disease.


Eligibility criteria:
inclusion criteria: * adults aged 18 years and above. * newly diagnosed with hypertension, defined as having a systolic blood pressure ≥ 140 mmhg and/or diastolic blood pressure ≥ 90 mmhg, confirmed by medical records or a recent health examination. * willing to provide a fecal sample for microbiota analysis. * able to give informed consent. * have not undergone any pharmacological treatment. exclusion criteria: * individuals with a history of chronic gastrointestinal diseases, such as inflammatory bowel disease or irritable bowel syndrome, which could independently affect gut microbiota. * use of antibiotics, probiotics, or prebiotics within the last three months, as these can alter the natural state of the gut microbiota. * presence of other significant chronic diseases like diabetes, severe renal or liver diseases, or heart failure. * pregnancy, as it can lead to physiological changes influencing gut microbiota. * history of bariatric surgery or any other major gastrointestinal surgery. * currently on medications known to significantly affect blood pressure other than standard antihypertensive treatments.
platelet inhibitor treated patients with head injury trauma meeting nice criteria : is the ct-scan mandatory ?

Conditions: Head Injury Trauma; Emergencies

Summary: at the emergencies rooms, patients with head trauma meeting one of the nice criteria, which include antiplatelet inhibitors treatment, are considered as patients with a risk of cerebral haemorrage and are taken systematically for a ct-scanner. however, there are more and more antiplatelet inhibitor's patient with minor head injury traumas seen at the emergencies room and the efficiency of this nice criteria is controversial on litterature. this study aims to determine that the absence of no other nice criteria than antiplatelet inhibitors is a sufficient condition to eliminate a cerebral haemorrhage for patients with head injury traumas, and conversely, that antiplatelet inhibitors treatment would not be by itself an indication for a ct-scanner.

head injuries are a frequent reason for emergency services, and according to studies, they represent between 5% and 10% of patients treated in emergencies. among them, 90% are minor head injury traumas. nice criteria has been defined to establish patients who need a ct-scanner because of a risk of cerebral haemorrhage. nice criteria include several conditions including taking antiplatelet inhibitors. however, the real risk of cerebral haemorrhage for theses cases is controversial in litterature. in parallel, more and more patients undergoing antiplatelet inhibitor's treatment are seen in emergencies after a head injury trauma. in routine protocol at the emergency rooms, these patients are seen for a clinical exam and next submitted to a ct-scanner. if the clinician can't detect a cerebral haemorrage, the patient will return at home. this study aims to determine that the absence of no other nice criteria than antiplatelet inhibitors treatment is a sufficient condition to eliminate a cerebral haemorrhage for patients with head injury traumas, and conversely, that antiplatelet inhibitors treatment would not be by itself an indication for a ct-scanner. this is a diagnostic, case-only, prospective, multicenter study with a blinded primary outcome measure assessment. as described in routine protocol, in this study antiplatelet inhibitor's patients with head injury trauma will be seen for a clinical exam and next submitted to a ct-scanner. after a month, patient will be called by the clinical center to ask about morbidity and mortality. especially, clinicans will report on the emergence of a cerebral haemorrhage during this month.

Eligibility criteria:
inclusion criteria: * at least 18 years old * patient with a head injury trauma, described by the patient or seen at the clinical exam * glasgow score between 13 and 15 at the clinical exam * current treatment with antiplatelet inhibitors * informed non opposition form signed exclusion criteria : * absence of ct-scanner * patients with double anti-platelet aggregation * patients on anticoagulants

Keywords: emergencies platelet inhibitors minor head injury trauma ct-scan
active surveillance vs in office fulguration for low grade bladder cancer tumors

Conditions: Bladder Cancer

Summary: biological behabiour of low grade bladder cancer tumors is well known. they have a very high rate of recurrences during their follow up but very low (less than 1%) risk of progression. until now, the gold standard of any bladder recurrence for this patients is performing an immediate transurethral ressection of the tumor. this surgery has risk of complications and, due to the low risk of these subgroup of tumors, sometimes it becomes an overtreatment for the patients. this is the reason why new conservative or less invasive surgeries are proposed to follow up and treat these patients.


Eligibility criteria:
inclusion criteria: * recurrent ta-t1a (above muscularis mucosa) low grade bladder tumor * accept cystoscopy surveillance * main lession less than 10mm * less than 7 lesions * negative or low grade cytology * no solid aspect exclusion criteria: * previous high grade bladder cancer tumors * previous cis * previous upper urinary tract tumor * previous pelvic radiotherapy * hematuria * meatal localisation

Keywords: active surveillance fulguration bladder cancer
optimized medico-pharmaceutical collaboration in the drug management of patients with heart failure

Conditions: Heart Failure

Summary: this is a controlled, randomized, open-label, multicentric study evaluating the value of coordinated medico-pharmaceutical management compared to standard management in patients with heart failure. the aim of this study is to evaluate the impact of these optimized activities on the re-hospitalization of the patient with cardiac insufficiency for a disease-related event within three months of the initial hospitalization.

heart failure (fh) is a public health problem with an estimated prevalence of about 1.5% in developed countries. in 2013, the number of patients hospitalized in france for heart failure amounted to 165 231 and 20% of them were re-hospitalized at least once for the same reason during this year. several factors contribute to the occurrence of cardiac decompensation (dc) : some modifiable (age, severity of ic, etiology ...) and others modifiable, such as therapeutics. various elements could reduce the frequency of re-hospitalizations and the mortality due to this disease : * a better knowledge of treatments by patients and consequently a better therapeutic compliance * a better knowledge of the factors and signs of dc (low-sodium diet, weighing...) * a better implementation of prescribing recommendations : less than 50% of patients have optimal treatment compared to esc recommendations * a better communication at the transition points of the patient pathway. the creation of a binomial cardiologist-clinical pharmacist during hospitalization and the maintenance of this optimized multidisciplinary follow-up within 3 months post-hospitalization is a proposal to intervene on these factors. indeed, the clinical pharmacist (present in the care unit) works in collaboration with the medical and paramedical teams and can improve the care of patients. in the experimental group, a specific multidisciplinary consultation is planned for one month after the end of the hospitalization. a 3-month follow-up visit will be carried out by phone call to meet the criteria for readmission, mortality, quality of life, adherence and persistence of treatments.

Eligibility criteria:
inclusion criteria: * patient aged more than 18 years * adult patient admitted in cardiology department (full hospitalisation or intensive care) for heart failure no matter the type and the stage of the disease * person affiliated or beneficiary of a social security system * collection of a free, informed, express and written consent exclusion criteria: * non autonomous drug management patients and not disposing * a present caregiver during hospitalisation * patients living in an institution * person participating in another clinical trial with an exclusion period still ongoing * person whose physical and/or psychological health is severely altered, and which, in the opinion of the investigator, may affect the participation's to the study * person deprived of his rights, person under tutorship or guardianship * refusal to sign the consent

Keywords: heart failure pharmacist multidisciplinary team readmission
management of uterine leiomyomata and adenomyosis

Conditions: Abnormal Uterine Bleeding

Summary: 1. to determine the role of hysteroscopy and guided biopsy to differentiate between submucosal fibroids and adenomyosis confirmed by histopathological examination 2. to evaluate the efficacy of norethisterone in the treatment of symptomatic adenomyosis and leiomyoma

the aim of the present study is: 1. to determine the role of hysteroscopy and guided biopsy to differentiate between submucosal fibroids and adenomyosis confirmed by histopathological examination 2. to evaluate the efficacy of norethisterone in the treatment of symptomatic adenomyosis and leiomyoma

Eligibility criteria:
inclusion criteria: - (1) age≥30 years; (4) dysmenorrhea, adenomyosis-associated chronic pain, and/or menorrhagia. (3) regular menstrual cycles before administration of norethisterone; (4) no other treatment for adenomyosis/leiomyomatosis at least for 3 months biopsies and histopathology for operated patients; exclusion criteria: * (1) pregnant and/or breast-feeding women (2) patients with a ovarian neoplasm, benign ovarian cyst including endometrioma, pelvic inflammatory disease or other endocrine diseases.
an observational study of roactemra/actemra (tocilizumab) in patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this observational, prospective, open-label, multi-center study will evaluate the effectiveness in disease reduction and the safety of roactemra/actemra (tocilizumab) in patients with rheumatoid arthritis. data will be collected for 11 months.


Eligibility criteria:
inclusion criteria: * adult patients \>/=18 years of age * patients with rheumatoid arthritis eligible for roactemra exclusion criteria: * hypersensitivity to roactemra * active, severe infections
rifaximin treatment of papulopustular rosacea

Conditions: Rosacea

Summary: the purpose of this study is to determine the effects of rifaximin on skin symptoms in patients with rosacea by double-blinded, placebo-controlled, crossover study.

100 patients will be randomized into two groups. group a will receive one rifaximin 550 mg tablet three times a day (1650 mg/day) for 14 days, and after a 4-week washout period, receive one placebo tablet three times a day for 14 days. group b will receive placebo first, and then rifaximin with the same dosage schedule to group a. assessments will be performed before application and 4 weeks after the last dosage, for both of rifaximin and placebo.

Eligibility criteria:
inclusion criteria: * males and females * \> 18 years of age with rosacea defined as: * 3-40 papules/pustules and \< 2 nodules, * a score of 2-4 on the investigator global assessment exclusion criteria: * untreated pancreatic insufficiency * crohn's disease * ulcerative colitis * active celiac disease by clinical history * end stage renal failure * less than 18 years old * pregnancy or positive pregnancy test * rosacea subtype 1 (no papules ) * topical or oral antibiotics within 4 weeks * acne treatments within 4 weeks prior to randomization * systemic retinoids within 90 days * topical or systemic corticosteroids 4 weeks prior to randomization

Keywords: rosacea
diabetes to go: an inpatient diabetes survival skills education program

Conditions: Diabetes Mellitus; Hyperglycemia

Summary: a learner-centered diabetes survival skills self-management education program was provided to adults with uncontrolled diabetes in the hospital and generated preliminary evidence of impact on medication adherence and a trend toward reduction in hospital and emergency department admissions.

this study was a prospective, nonrandomized pilot study conducted among adults with uncontrolled diabetes admitted to the medicine service of an urban tertiary teaching hospital were consented to participate in a pilot study which provided diabetes survival skills education. based on knowledge deficits identified on a diabetes knowledge pre-test the patient was directed to view video content corresponding to those deficiencies and content on sick days and diabetes complications. evaluation measures were diabetes knowledge, medication adherence, and hospital admissions plus emergency department visits at and/or 3months before baseline and at 2 weeks and 3 months post-discharge. there was improvement in diabetes knowledge and medication adherence, which was sustained to 3 months. a trend was observed toward reduction in emergency department and/or hospital admissions from 3 months pre-intervention to 3 months post-discharge for uncontrolled diabetes. this knowledge-based program successfully provided survival skills education to hospital patients with uncontrolled diabetes and demonstrated preliminary evidence of a positive impact on medication adherence and a trend toward reduction in hospital and emergency department admissions.

Eligibility criteria:
inclusion criteria: * english speaking with a diabetes mellitus diagnosis (icd 9 codes 250.xx) * an admitting blood glucose level of \> 200 mg/dl or ≤ 40 mg/dl, and * an anticipated hospital stay of ≥ 2 days, as estimated by the medical staff, to allow sufficient time for delivery of program content exclusion criteria: * pregnancy * admission to an intensive care unit, and * any medical condition or cognitive dysfunction that, in the opinion of the investigator, would preclude active participation

Keywords: diabetes mellitus hyperglycemia inpatient self-management education
sprmpik ai sperm selection study sid, an assistant for sperm selection during intracytoplasmic sperm injection in medically assisted reproduction: effect on fertilization, blastocyst formation, early pregnancy loss, and consistent practice. a prospective pilot study.

Conditions: Infertility

Summary: sprmpik ai assisted sperm selection study sid, an assistant for sperm selection during intracytoplasmic sperm injection in medically assisted reproduction: effect on fertilization, blastocyst formation, early pregnancy loss, and consistent practice. a prospective pilot study.

the purpose of this research is to evaluate the impact of sperm selection for icsi using the investigational sid software, on performance outcomes such as the rate of fertilization, blastocyst development, clinical pregnancy success, and other intermediate results, in a pilot study. sid is a software designed to identify, evaluate, and assist in the sperm selection process within a semen sample, according to motility (for instance velocity, linearity, straightness) patterns and the shape of the sperm. sid uses a mathematical model. its purpose is to assist clinical embryologists in selecting sperm to inject during icsi. currently, embryologists identify and select sperm based on the sperm motility and shape; not using any mathematical interphase assistant.

Eligibility criteria:
inclusion criteria for male partner (sperm source) * informed consent signed by the patient before treatment. * ivf treatments with medical or embryology indication to perform icsi. * fresh or frozen ejaculated motile sperm. * selection of sperm using a 7% or 10% pvp solution. * presence of motile sperm at the time of sperm selection for icsi. * partner sperm exclusion criteria for male partner (sperm source) * sperm extracted by testicular biopsy. * that the recommendations for use of sid have not been fully followed. * inability to reliably trace sperm-oocyte-embryo throughout the process. * patients with immotile sperm inclusion criteria for female partner (egg source) * informed consent signed by the patient before treatment. * ivf treatments with medical or embryology indication to perform icsi. * cycles with at least 4 mature oocytes (metaphase ii). * fresh or frozen oocytes. exclusion criteria for female partner (egg source) * inability to reliably trace sperm-oocyte-embryo throughout the process. * oocytes that are not in metaphase ii.
the effect of neuromuscular electrical stimulation

Conditions: Postoperative Coronary Artery Bypass Grafting (CABG); Chronic Obstructive Pulmonary Disease (COPD); Ventilatory Failure

Summary: the effect of neuromuscular electrical stimulation on muscle atrophy in sedated patients on intensive care was studied. the aim of this study was to explore if electrical stimulation could prevent muscle atrophy.

patients were included in the study one day after administration when prolonged sedation and ventilation were expected. they were divided into intervention (n=7) and control (n=14) groups. for the intervention group, an intermittent neuromuscular electrical stimulation was applied daily for 30 minutes on the right thigh whereas the left thigh was used as a control. heart rate, respiration rate, systolic and diastolic blood pressure and oxygen saturation were monitored before, during and after the electrostimulation. perimeter of the right and left thighs was measured in both groups every 3 days at 5 cm above the upper edge of the kneecap.

Eligibility criteria:
inclusion criteria: * . prior to inclusion in the study, an informed consent was given by the family of the patients which was approved by the local ethics committee of the virga jesse hospital and was performed in accordance with the standards of the 1964 declaration of helsinki. exclusion criteria: * patients were excluded from the study if they were still able to move their limb actively in spite of the sedation. patients were also excluded if they had signs of recent ischemia or infarction for less then seven days. patients with severe orthopaedic or vascular damage, i.e., fractures or oedema in the lower limbs were also excluded. patients with an augmented risk for neuro electrical stimulation such as open wounds, hemodialysis or an arterial catheter at the stimulation area were also excluded.

Keywords: functional electrical stimulation muscular atrophy intensive care